论文部分内容阅读
本研究在前一阶段工作的基础上,进一步缩短了15-甲PGF_(2α)疗程和减少用药量,并以β-hCG放射免疫测定为主要指标,观察抗早孕效应。停经49天以内的60例早孕妇女随机分为两组,每组30例。组Ⅰ的15-甲PGF_(2α)最高用量为10毫克,组Ⅱ为8毫克;两组用药疗程均为8小时(比以前缩短4小时)。丙酸睾丸酮用法同前。结果两组抗早孕有效率分别为96.67%和100%(p>0.05);15-甲PGF_(2α)平均用量分别为9.67±0.21和7.70±0.19毫克(p<0.05)。组Ⅱ用药比组Ⅰ少2毫克,更适于门诊推广应用。本文并对β-hCG放射免疫测定在药物抗早孕研究中的应用及丙酸睾丸酮的抗早孕机理进行了讨论。
Based on the previous work, this study further shortened the course of 15-A PGF 2α treatment and reduced the dosage. Β-hCG radioimmunoassay was used as the main index to observe the anti-pregnancy effect. 60 cases of early pregnant women within 49 days after menopause were randomly divided into two groups, 30 cases in each group. The maximum dosage of 15-A PGF 2α in group I was 10 mg and that in group II was 8 mg. Both groups were treated for 8 hours (4 hours shorter than before). Testosterone propionate use the same as before. Results The effective rates of anti-pregnancy in the two groups were 96.67% and 100% respectively (p> 0.05). The average dosage of 15-A PGF 2α was 9.67 ± 0.21 and 7.70 ± 0.19 mg respectively (p <0.05). Group Ⅱ medication less than group Ⅰ 2 mg, more suitable for out-patient promotion and application. In this paper, β-hCG radioimmunoassay in the study of drug anti-early pregnancy and testosterone propionate anti-early pregnancy mechanism are discussed.